Ocular Therapeutix, Inc. (OCUL) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

9/25

Growth 2 Margin 2 Expansion 3 Platform 1 Financial 1

latest quarter score

Earnings Reports

9
Ocular Therapeutix (OCUL) Q1 2026: SOL1 Superiority Data Drives NDA Momentum and 12-Month Disease Control Narrative
May 05, 2026
9
Ocular Therapeutix (OCUL) Q3 2025: $445M Financing Extends Cash Runway, Accelerates Expaxly Phase 3 Ambitions
November 04, 2025
9
Ocular Therapeutix (OCUL) Q2 2025: $97M ATM Raise Extends Runway as Sol Trials De-Risk Superiority Label
August 05, 2025
Ocular Therapeutix (OCUL) Q4 2024: Registrational Program Streamlining Accelerates NDA Path with 33% Trial Size Reduction
March 03, 2025

Browse all companies